Last edition
News about "SIK3 Inhibitor O3R-5671 "
Onco3R Therapeutics Secures Approval to Launch First-in-Human Trial of SIK3 Inhibitor O3R-5671
Onco3R Therapeutics is expected to start enrolling subjects for the first-in-human trial of SIK3 inhibitor O3R-5671 over the coming weeks, with dosing of the first subject anticipated later in September.
SIK3 Inhibitor O3R-5671 | 04/09/2025 | By Dineshwori | 173
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members